Phase 3 Startup Activities are Underway, with Trial Initiation Expected in Q1 2024FARMINGTON HILLS, Mich., Jan. 04, 2024 (GLOBE NEWSWIRE)…
Strategic Process Underway to Explore Partnering Opportunities for Additional Indications such as with GLP-1s for Obesity and Metabolic Disorders and…
-- Positioned for three Phase 3 trial readouts over the next 18 months -- -- Topline data expected from Phase…
LSTA1, the Company’s lead investigational product, in combination with standard-of-care therapy, potentiated a complete response in a patient with metastatic…
Patent will provide additional protection covering a composition targeting any viral infection, including hepatitis B, HIV, and influenzaNEW YORK, Jan.…
Pleasanton, CA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Peak Bio, Inc. ("Peak Bio" or the "Company") (OTCQB) PK: PKBO), announced that…
Four development candidates anticipated to be in the clinic by the end of 2024, reflecting expansion of R&D portfolio across…
Poised for multiple meaningful catalysts in 2024 driven by strong clinical progress across large market programs in wet age-related macular…
Media Release SYDNEY, AUSTRALIA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”),…
Study with YUTIQ® has Surpassed Goal of 100 Patients EnrolledATLANTA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq:…